Patents by Inventor Daniel Burdick

Daniel Burdick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating cardiovascular disease
    Patent number: 11034725
    Abstract: The invention provides PCSK9 inhibitors, compositions comprising the PCSK9 inhibitors, and methods of identifying and using the PCSK9 inhibitors.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: June 15, 2021
    Assignee: Genentech, Inc.
    Inventors: Maureen Beresini, Daniel Burdick, Charles Eigenbrot, Jr., Daniel Kirchhofer, Robert Lazarus, Wei Li, John Quinn, Nicholas Skelton, Mark Ultsch, Yingnan Zhang
  • Compositions and methods for treating cardiovascular disease
    Patent number: 10787484
    Abstract: The invention provides PCSK9 inhibitors, compositions comprising the PCSK9 inhibitors, and methods of identifying and using the PCSK9 inhibitors.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: September 29, 2020
    Assignee: Genentech, Inc.
    Inventors: Maureen Beresini, Daniel Burdick, Charles Eigenbrot, Jr., Daniel Kirchhofer, Robert Lazarus, Wei Li, John Quinn, Nicholas Skelton, Mark Ultsch, Yingnan Zhang
  • COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE
    Publication number: 20200283478
    Abstract: The invention provides PCSK9 inhibitors, compositions comprising the PCSK9 inhibitors, and methods of identifying and using the PCSK9 inhibitors.
    Type: Application
    Filed: May 26, 2020
    Publication date: September 10, 2020
    Applicant: Genentech, Inc.
    Inventors: Maureen Beresini, Daniel Burdick, Charles Eigenbrot, Jr., Daniel Kirchhofer, Robert Lazarus, Wei Li, John Quinn, Nicholas Skelton, Mark Ultsch, Yingnan Zhang
  • COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE
    Publication number: 20190177366
    Abstract: The invention provides PCSK9 inhibitors, compositions comprising the PCSK9 inhibitors, and methods of identifying and using the PCSK9 inhibitors.
    Type: Application
    Filed: December 21, 2018
    Publication date: June 13, 2019
    Applicant: Genentech, Inc.
    Inventors: Maureen Beresini, Daniel Burdick, Charles Eigenbrot, JR., Daniel Kirchhofer, Robert Lazarus, Wei Li, John Quinn, Nicholas Skelton, Mark Ultsch, Yingnan Zhang
  • Substituted pyrrolo[2,3-b]pyrazines as serine/threonine kinase inhibitors
    Patent number: 9382257
    Abstract: Compounds having the formula I wherein R1 and R2 are as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: July 5, 2016
    Assignee: Genentech, Inc.
    Inventors: Daniel Burdick, Huifen Chen, Shumei Wang, Weiru Wang
  • SERINE/THREONINE KINASE INHIBITORS
    Publication number: 20150218176
    Abstract: Compounds having the formula I wherein R1 and R2 are as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Application
    Filed: April 16, 2015
    Publication date: August 6, 2015
    Applicant: Genentech, Inc.
    Inventors: Daniel Burdick, Huifen Chen, Shumei Wang, Weiru Wang
  • Antagonists for treatment of CD/11CD18 adhesion receptor mediated disorders
    Publication number: 20050203135
    Abstract: Compounds of the general structure D-L-B-(AA), for example (A), that are useful for treating Mac-1 or LFA-1-mediated disorders such as inflammatory disorders, allergies, and autoimmune diseases are provided.
    Type: Application
    Filed: August 26, 2003
    Publication date: September 15, 2005
    Inventors: Daniel Burdick, Thomas Gadek, Robert McDowell, James Marsters, David Oare, Mark Reynolds, Mark Stanley, Kenneth Weese
  • LFA-1 antagonist compounds
    Publication number: 20050148588
    Abstract: The invention relates to novel compounds having formula (I) wherein Cy, X, Y, L and R1-6 are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.
    Type: Application
    Filed: January 21, 2005
    Publication date: July 7, 2005
    Inventors: Daniel Burdick, Mark Stanley, David Oare, Mark Reynolds, Thomas Gadek, James Marsters